FDA OKs Intravenous Tocilizumab Biosimilar in Cytokine Release Syndrome
Written by
Cancer Network
Published
0
comments
0
min
The intravenous formulation of tocilizumab-anoh for CRS is expected to launch in the US on August 31, 2025.